BC
REGN icon

Barnett & Company’s Regeneron Pharmaceuticals REGN Stock Holding History

Barnett & Company’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-103
Closed -$50K – 351
2020
Q1 		$50K Sell
103
-3
-3% -$1.24K 0.05% 133
2019
Q4 		$40K Buy
106
+103
+3,433% +$34.7K 0.02% 186
2019
Q3 		$1K Buy
+3
New +$888 ﹤0.01% 399

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Barnett & Company's REGN Position: Q2 2020 in Review

Barnett & Company sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 103 shares — an estimated $50K sold.

Barnett & Company first reported a position in REGN in Q3 2019 and held it in 3 quarters. The position peaked at $50K in Q1 2020. 932 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Barnett & Company reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Barnett & Company sold 103 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $50K.
  • Barnett & Company first reported a position in Regeneron Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Barnett & Company's Regeneron Pharmaceuticals position peaked at $50K in Q1 2020.
  • 932 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Barnett & Company's 13F filing for Q2 2020, filed 22 Jul 2020.